Literature DB >> 10354966

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.

R P Nath1, R A Upton, E T Everhart, P Cheung, P Shwonek, R T Jones, J E Mendelson.   

Abstract

Buprenorphine is an effective new treatment for opiate dependence. This study compared the bioavailability of buprenorphine from a tablet to that from a reference solution. Six men experienced with, but not dependent on, opiates (DSM-III-R) were each administered 7.7 mg of buprenorphine in liquid form and 8 mg in tablet form 1 week apart in a balanced crossover design. Plasma levels were measured by electron capture capillary gas chromatography (GC), and concentration-time curves were constructed. Pharmacokinetic data were analyzed by analysis of variance. The bioavailability from the tablet was approximately 50% that from the liquid and was not affected by saliva pH. Lower bioavailability from the tablet may be due to slow dissolution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354966     DOI: 10.1177/00912709922008236

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  28 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 3.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 5.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

6.  Medication-assisted treatment for opioid addiction: methadone and buprenorphine.

Authors:  Andrew J Saxon; Yih-Ing Hser; George Woody; Walter Ling
Journal:  J Food Drug Anal       Date:  2013-12       Impact factor: 6.079

7.  Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Authors:  Debra S Harris; John E Mendelson; Emil T Lin; Robert A Upton; Reese T Jones
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry.

Authors:  Karen J Regina; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-09-08       Impact factor: 3.205

10.  Buprenorphine for opioid dependence.

Authors:  Walter Ling
Journal:  Expert Rev Neurother       Date:  2009-05       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.